In this paper, we investigate a previously proposed mathematical model describing the effects that an innovative combined radiopharmaceutical therapy might have on the delivery of radiation to the tumor and limiting critical organs. While focused on a specific dual agent therapy, this investigation will prove mathematically that for any two therapeutic radiopharmaceuticals with different limiting critical organs the model provides patient specific conditions under which combination therapy is superior to single agent therapy. In addition, this paper outlines general methods for calculating the amounts of administered radioactivity for each drug required to optimize tumor radiation dose. We also consider extensions of this model to include an arbitrary number of independent radiopharmaceuticals and/or other treatment factors.
Introduction
Effective treatments for patients with disseminated neuroendocrine tumors are limited. Many subjects with carcinoid syndrome will respond dramatically to octreotide therapy but for only a limited time (1). Chemotherapy is generally ineffective except in the more aggressive neuroendocrine tumors such as neuroblastoma. Even so, currently long term survival for advanced stage neuroblastoma is achieved in only 30% of patients (2) . Similarly, patients with metastatic carcinoid have a limited 5-year survival in the range of 25-50% (3).
Targeted radionuclide therapy with 131 I-metaiodobenzylguanidine ( 131 I MIBG), 90 Y DOTA-Phe 1 -Tyr 3 Octreotide ( 90 Y DOTATOC), or 177 Lu DOTA-Tyr 3 -octreotate ( 177 Lu DOTATATE) has shown substantial promise in patients with neuroendocrine tumors not responsive to other treatments (4-10). Studies have demonstrated similar radiographic response rates for these three agents ranging from 20-40% depending somewhat on tumor type and the specific administration protocol (5, (11) (12) (13) (14) (15) (16) . Unfortunately, complete responses are notably uncommon, occurring usually in less than 10% of patients and response duration is often Technology in Cancer Research & Treatment, Volume 8, Number 1, February 2009 disappointing as well (5, 12, 17, 18) . The effectiveness of these targeted radionuclide treatments is limited primarily by the radiation dose to the tumor that can be achieved without causing substantial toxicity to normal organs.
Pre-therapy individual patient dosimetry measurements have indicated that a total tumor dose of approximately 7,000 cGy or greater from 131 I MIBG is likely to lead to good tumor response in neuroblastoma (18, 19) . Interestingly, recent data suggests a similar 8-10,000 cGy total tumor dose will yield good response in neuroendocrine tumors (which were predominately carcinoid tumors) treated with 90 Y DOTATOC (20) . However, these tumor dose levels (i.e., 7,000-10,000 cGy) are infrequently achieved with either of these radionuclide agents. There is, therefore, a need for new approaches to enhance the tumor radiation dose delivered by these radiopharmaceuticals without exceeding normal organ limits. One of these approaches, not previously investigated, is delivery of both agents in combination based on individualized dosimetry measurements as proposed in our model. MIBG and DOTATOC/DOTATATE are concentrated in tumor cells by entirely different physiologic processes. 90 Y DOTATOC is a somatostatin (SST) analog with very high affinity for the subtype 2 SST receptor (with lesser affinity for subtype 5) present in high concentration in most types of neuroendocrine tumors (11, 21) . 177 Lu DOTATATE is another SST analog that has a similar (although not identical) biodistribution and tumor uptake pattern to 90 Y DOTATOC (22) . In contrast to these agents, 131 MIBG is actively concentrated in neuroendocrine tumor cells by the type 1 norepinephrine uptake mechanism (23, 24). There are also substantial differences in the normal organ biodistribution of 131 I MIBG compared to 90 Y DOTATOC and 177 Lu DOTATATE that lead to substantially different radiation absorbed doses to important normal organs such as kidney and bone marrow for these agents (10, (25) (26) (27) . By exploiting these major differences in the critical dose-limiting organs for each agent, we have shown previously that it is possible to combine large fractions of the maximum tolerated administered activity of each individual drug into a single treatment regimen that delivers greater radiation dose to the tumor without exceeding the critical organ toxicity (28). This should lead then to potentially greater anti-tumor effects. Our unique approach combining two therapeutic radiopharmaceuticals into a single treatment regimen will take advantage of differing mechanisms of tumor uptake and different normal tissue distribution for these agents to increase the radiation dose delivered to tumor sites without increasing normal tissue toxicity.
We present here a re-examination of the original model (29) in a more mathematical context and introduce an alternative approach for determining the optimal dosages for combination radioactive drug treatment. This approach uses the theory of linear programming to achieve results similar to those in our earlier work with the additional advantage that the approach is easily modified to calculate optimal dosages should the model be extended to include other factors such as drug costs or additional radiopharmaceuticals.
The Model
The model investigated in this paper was conceived initially to study combined agent therapy using 90 Y DOTATOC and 131 I MIBG, two radiopharmaceuticals used in the treatment of neuroendocrine tumors. However, the methods and mathematics described in this paper have been generalized to accommodate any combination of radiopharmaceuticals that have different limiting critical organs. We will refer to organ 1 and organ 2 as the limiting critical organs associated with drug 1 and drug 2, respectively.
The problem of determining the optimal activity combination of drug 1 and drug 2 can be reduced to a linear constrained optimization problem (aka linear program) in two variables. The parameters a, b, c, d, t 1 , and t 2 are all measurable values for an individual patient. The task is to determine values for X and Y, which maximize t 1 X + t 2 Y subject to the constraints that aX + bY not exceed L 1 and cX + dY not exceed L 2 .
In standard mathematical form this problem is as follows:
Maximize: t 1 X + t 2 Y Subject to: aX + bY ≤ L 1 cX + dY ≤ L 2 X, Y ≥ 0
We propose and will prove that neither X nor Y will equal zero when the following conditions exist:
That is, we claim the following conjecture is true:
If the therapeutic index for drug 1 is less than the ratio (tumor : organ 1) for drug 2 and the therapeutic index for drug 2 is less than the ratio (tumor : organ 2) for drug 1, then combined therapy delivers a greater dose of radiation to the tumor than the administration of either drug 1 or drug 2 alone.
For the remainder of this paper we will use the equivalent, but more concise, version of these conditions:
[1]
Graphical Interpretation of the Model
The existence of a solution to the above optimization problem relies on the geometry of the problem. Two wellknown theorems can be used to determine when and where a solution exists:
Extreme Value Theorem:
If a function is continuous on a compact (closed and bounded) set, then it attains a maximum (optimal solution) on that set.
Fundamental Theorem of Linear Programming:
If a linear program has a bounded, optimal solution, then there exists an extreme point (i.e., a vertex) of the feasible region, which is optimal.
The function Z = Z(X,Y) = t 1 X + t 2 Y (called the objective function) is continuous on the XY-plane. Therefore, on any closed and bounded subset of the XY-plane, Z attains a maximum and minimum value. In this context, we consider a set to be closed if it includes every portion of its boundary. As an example, compare the sets of points that satisfy inequality X 2 + Y 2 < 9 with those satisfying the inequality X 2 + Y 2 ≤ 9. The set of points satisfying the first are all points whose distance is strictly less than 3 from the origin. This set is not closed since its boundary is the circle centered at the origin whose radius is equal to 3 and the points on this circle do not satisfy the inequality. The set of points satisfying the second inequality is a closed set since it includes the points on that circle. We consider a set to be bounded if every point in the set is closer to the origin [the point (0,0)] than some finite upper bound. For example, the set of points which make up quadrant I of the XY-plane [i.e., the points (X,Y) such that X > 0 and Y > 0] is not a bounded set since it contains points arbitrarily far from the origin. To convince the reader that the model generates a closed and bounded domain, let us consider the geometry that is generated by our constraints. Our constraints can be rewritten in the following form:
with a, b, c, d, L 1 , L 2 > 0.
The set of (X,Y) pairs, which simultaneously satisfy both constraints and the non-negativity requirements, make up the region of feasibility. Since the a, b, c, and d are required to be positive, we are assured that the boundaries defined by the first two constraints are lines with negative slope and positive Y-intercept, both constraint lines will intersect the positive X-and positive Y-axes. The ≤ signs and the nonnegativity requirements on X and Y ensure that the regions in question are those bounded by each of these lines and by the positive X-and Y-axes. In general, there are two possible geometries to consider: One in which the constraint lines intersect in the first quadrant and one in which they do not. In the first case, the region of feasibility (Figure 1 ) is the intersection of two right triangles whose hypotenuses cross (i.e., a closed, bounded quadrilateral).
In the second case, we have redundancy in the constraints ( Figure 2 ) as only one constraint line is necessary to define the region of feasibility. Note, that redundancy is merely a mathematical artifact of the model, and will not occur in practice as long as the two radiopharmaceuticals have differ- ent limiting critical organs, so we will not consider this case.
The Extreme Value Theorem allows us to conclude that the region of feasibility contains a maximal solution to Z = t 1 X + t 2 Y. Invoking the Fundamental Theorem of Linear Programming leads us to the conclusion that the maximum value of Z = t 1 X + t 2 Y must occur at one of the four vertices of our region of feasibility.
The following facts are noteworthy. First, the homogeneity of the objective function renders the vertex at (0,0) trivial as this corresponds to the administration of neither radiopharmaceutical and, thus, no dose to the tumor. Obviously, no method to determine optimality should consider this point.
Second, in the case that either , the optimal solution will occur at every point on the line segment joining two adjacent vertices. The geometry that gives rise to this situation will become evident in the following section.
In the improbable situation that either of these equalities is achieved, the administration of a maximal activity of a single agent will have the same effect as the optimal combined activities, so this situation will not be considered.
Proof of the Optimality Conditions
Our claim is that given two radiopharmaceuticals with different limiting critical organs, combined agent therapy is superior to single agent therapy whenever the conditions [1] are met. In this section, two different proofs of this result are given. The first is a strictly geometric argument, which is meant only to guide the reader's intuition, and the second is a rigorous analytic proof.
Geometric Proof
Recall the region of feasibility generated by the conditions [1]. In addition, visualize the plane Z = t 1 X + t 2 Y above the region of feasibility in three dimensions. Consider the projection of the region of feasibility up onto the plane Z = t 1 X + t 2 Y (Figure 3 ). Then given any pair of administered activities (X 0 ,Y 0 ) in the region of feasibility, the height of this projection above that point corresponds to the resulting level of radioactivity administered to the tumor.
With little effort one can see that the level curves of the objective function over the region of feasibility are line segments with slope and that the inequality implies that this value is between , the slopes of the constraint lines associated with organ 1 and organ 2, respectively ( Figure 4 ).
So, on the XY-plane we have the next figure shown ( Figure 5 ). Note that the arrows perpendicular to the level curves indicate the direction of greatest ascent on the plane Z = t 1 X + t 2 Y.
As the level curves sweep across the region of feasibility as the Z-value of the level curve is increased, the points contained in these line segments correspond to feasible activity pairs, which yield ever increasing dose delivered to the tumor. To maximize the dose delivered to the tumor, one needs only to sweep these lines as far as possible across the region of feasibility. It is clear that if the level curves have slope between those of the constraint lines as they do in Figure 5 ; then the level curves will sweep towards the point of intersection of the two constraint lines, therefore indicating that the optimum choice of dosages is some combination of both drugs.
Likewise, if the parameter values are such that then the level curves will sweep towards the vertex correspond- ing to the administration of drug 1 alone and if the level curves will sweep towards the vertex corresponding to the administration of drug 2 alone. For completeness, an analytic proof of this result is provided in Appendix A.
The Method
With the existence of a solution guaranteed and knowledge of the conditions under which combined therapy is superior, it only remains to generate a method for determining the optimal activity for any given patient. What follows is a brief outline of such a method.
I. First check for redundancy in constraints. That is, ensure that the limiting critical organ for one drug is different from the limiting critical organ for the other. If no redundancy exists, then II. Check the condition . If the patient specific parameters satisfy this inequality, then one may conclude that combined therapy is superior and the optimal administered activity combination is . If the inequality is not satisfied, then III. Calculate the value of Z at the two remaining vertices. The administered activity associated with the vertex that yields the greatest Z-value selects the optimal single agent.
An implementation of this method can be tested on the web at www.math.uiowa.edu/~ibesse. With user defined inputs for the parameters a, b, c, d, t 1 , t 2 , a bone marrow radiation thresh-old, and a kidney radiation threshold one may calculate the optimal activity of a combined MIBG/DOTATOC treatment.
Alternatively, one could merely test each of the three "nontrivial" vertices in succession to determine if single agent 1, single agent 2, or the combined agents would result in the greatest delivery of radiation dose to the tumor. Simple substitution of the X and Y activities at each of these points into the formula for Z would determine which administered activity pair yielded the highest Z-value. However, this method, revisited at the end of the next section, would have more utility in cases where the model was extended to include three or more drugs in combination.
Extending the Model
This model has the advantage of having the capacity to incorporate a greater number of factors than we have so far utilized such as additional radiopharmaceuticals or drug costs.
Note that in this model, the two drugs (and consequently, two limiting critical organs) gave rise to a planar polygonal region of feasibility. The inclusion of n such drugs each with distinct limiting critical organs would produce a region of feasibility that was an n-dimensional polyhedron. Suppose we assign the i th drug's activity X i and its associated limiting critical organ L i . Then the problem takes on the form:
Maximize: t 1 X 1 + t 2 X 2 + … + t n X n Subject to: a 11 X 1 + a 12 X 2 + … + a 1n X n ≤ L 1 a 21 X 1 + a 22 X 2 + … + a 2n X n ≤ L 2 a n1 X 1 + a n2 X 2 + … + a nn X n ≤ L n with X i ≥ 0 and a ij patient specific parameters. Note that here a ij represents the radiation dose per unit of administered radioactivity (mGy/MBq) from drug j to organ i. Consider for example a scenario in which many drugs are being used in combination. If 131 I MIBG is assigned to be drug 7 and the kidneys are assigned to be limiting organ 4, then a 47 represents the dose to the kidneys from 131 I MIBG.
This can be stated more concisely in matrix-vector form as:
Maximize:
Subject to:
where A is the matrix [a ij ].
In such a linear optimization problem, the region of feasibil- ity will always be a convex polyhedron with a finite set of vertices and due to the Fundamental Theorem of Linear Programming, the optimal combination delivering the greatest amount of radiation to the tumor will necessarily occur at one of these vertices. Note that the factors represented by the variables are not limited to the administered radioactivity for each drug; they could represent any relevant treatment factor. For instance, the variables a ik could represent cost of each drug X i . Then L k is the upper bound imposed on the total cost of the treatment.
Recall that in the two drug model, there was a relatively simple set of clinically relevant conditions related to the therapeutic indices that determined whether combined agent therapy was superior to single agent therapy. In contrast, once additional variables are introduced, the model becomes complicated enough that such simple clinically relevant conditions are not easily derived. Nonetheless, while a quick check of whether combined agent therapy is superior may not exist in these cases, there exists an enormous body of mathematical theory related to methods for determining the optimal activity combination in such high dimensional cases.
For instance, the vertices of the multi-dimensional polyhedral region of feasibility are easily determined, and in the absence of more sophisticated approaches, one could merely check the administered radioactivity to the tumor for each one. However, a number of more sophisticated and efficient methods do exist. The simplex method is one such method in which the search from one vertex to another is mediated by the requirement that the value of the objective function increase at each step in the search. A variety of so-called interior point methods are also quite applicable to this sort of optimization problem as well (30). Therefore, it is a simple matter to extend the model to include any number of variables and the mathematical machinery needed to determine optimal activity in these cases is well established.
Results and Discussion
In this section, we consider a dual agent treatment using the (potentially combined) radiopharmaceuticals 131 I MIBG and 90 Y DOTATOC. We provide three examples of reasonable patient parameter data and discuss optimal treatment protocol for each. In each case, the radiation threshold for the bone marrow (MIBG's limiting critical organ) is assumed to be 300 cGy (denoted by L 1 ) and the radiation threshold for the kidneys (DOTATOC's limiting critical organ) is assumed to be 2300 cGy (denoted by L 2 ).
Case 1
Given the following patient dosimetry parameter values, In general, successful clinical use of targeted radionuclide therapy for tumor eradication depends on the ability of the radioactive agent to deliver sufficient radiation dose to the tumor without severely damaging normal organs. This is best reflected by the therapeutic index that represents the ratio of radiation dose delivered to the target tumor divided by the radiation dose delivered to the most susceptible, and functionally critical, normal organ. If two radiopharmaceuticals have the same dose limiting normal organ, then the preferred treatment agent would be the one which yielded the highest therapeutic ratio for that patient.
Consider in contrast a scenario where the critical organs (e.g., kidney and red marrow) are not the same for the two therapeutic radiopharmaceuticals (kidney being the limiting organ in this case for 90 Y DOTATOC and bone marrow for 131 I MIBG). If both ratios (tumor/kidney and tumor/marrow) turn out to be larger for radiopharmaceutical #1 compared to #2, then there would be no possible value to adding this second agent to a therapeutic regimen of the first. However, as we have shown, when the tumor/kidney dose ratio is greater for one of the agents (essentially always MIBG) and the tumor/bone marrow ratio is greater for the other radiopharmaceutical (very often DOTATOC) then the agents can be combined in mathematically defined quantities to yield an overall "cumulative" therapeutic ratio for each critical organ, which is larger than the therapeutic ratios achievable when either radiopharmaceutical is delivered alone. As we have demonstrated previously and expand upon in this manuscript, the ability to determine a specific combination of administered activities for these two radioactive agents that will deliver a maximum dose to the tumor without exceeding the dose thresholds for either of the two critical organs providing that we know in advance the respective dose delivered per administered activity of each radiopharmaceutical for both tumor and critical organs (29). As we have already reported, the optimal combination of the agents can be determined by solving two simultaneous equations with two unknowns (e.g., X, Y as defined in this article) with additional equations to define the conditions where single agent administration is superior.
There may be other advantages for combining two agents such as 90 Y DOTATOC and 131 I MIBG into a single treatment that are unrelated to the dosimetric concept demonstrated here. It is reasonable to imagine that some tumors or regions within a tumor might target better with one agent as opposed to the other. Modest heterogeneity within a single tumor site generally does not pose a treatment problem for higher energy beta emitters such as 90 Y since radiation energy may be deposited in cells a cm or more distant from the emission. However, for lower energy beta emitters such as 131 I and 177 Lu this "crossfire" phenomenon may be effective for only a few mm. Consequently, treatment with a radiopharmaceutical that is distributed with substantial heterogeneity within a large single tumor site or unevenly among multiple distant tumor sites may be ineffective. If, however, a second agent is added that targets some of the sites not targeted by the other agent, the likelihood for therapeutic success should increase. There is very good evidence that some individuals will show better tumor targeting with MIBG whereas others will show better targeting with SST analogs (31, 32).
Additionally, it has been shown that some individuals demonstrate a combination of tumor sites with good SST analog uptake and poor MIBG uptake and vice versa (33). In a very recent study, 123I MIBG and 111 In pentetreotide imaging were both performed in 92 subjects with an existing diagnosis of metastatic carcinoid tumor (34). Thirty percent of the patients showed tumor sites with essentially the same level of uptake for each agent. Fifteen percent of subjects had a completely negative MIBG scan in the presence of 111 In pentetreotide positive lesions and 6% had completely negative pentetreotide images even though MIBG showed positive tumor sites. Most importantly fully 49% of the 92 subjects showed metastases that were pentetreotide positive/MIBG negative in addition to metastases that were MIBG positive/ pentetreotide negative. Finally there is also compelling data demonstrating that in some instances the relative distribution of MIBG and octreotide within a single tumor site may be substantially discordant (13, 23, 33, 35) .
There is a substantial difference in the maximum beta particle energy for the emissions from 131 I and 177 Lu compared to 90 Y (0.6 Mev, 0.5 MeV, and 2.3 MeV, respectively). For a one cm diameter tissue sphere with uniformly distributed radioisotope, approximately 50% of the beta energy from 90 Y will be deposited outside the sphere whereas in the case of 131 I and 177 Lu similar energy loss is not seen until the tissue sphere is reduced in size to roughly 1 mm (36). Theoretical considerations indicate that for beta particles from 131 I or 177 Lu it is likely that the optimal tumor diameter for therapy is on the order of only several mm (37, 38); whereas, for therapy with 90 Y the optimal tumor diameter is an order of magnitude larger. Recently, Dr de Jong and co-workers noted a substantial survival benefit in mice harboring multiple, various small and large sized tumor implants when treated with a combination of both 90 Y DOTATOC and 177 Lu DOTATATE compared to animals treated with either agent alone.
It is essential that kidney, tumor, and bone marrow dosimetry values be measured for each patient individually for our approach to work in practice. The necessary radiopharmaceutical biodistribution and kinetic information for radiation dose calculations can be obtained (albeit with some effort) in most Nuclear Medicine laboratories. Limitations in the accuracy achievable with current dosimetry methodologies can be expected to introduce some degree of error into the calculations for values of a, b, c, d, t 1 , and t 2 for a given individual. However, the current standard approaches for determining what amount of radioactive drug to deliver to a patient also suffer substantial limitations. The most commonly used method is to simply administer the same level of radioactive drug to each patient without regard for individual variations in drug distribution throughout the body. Very often these variations are substantial from one patient to another, creating large dif-ferences in radiation doses delivered to organs and tumors for a given amount of administered activity of the drug. In contrast, we believe the uncertainties in the measurement of individual dosimetry values for a given patient are relatively smaller than the inter-patient dosimetry variations discussed above. The error associated with estimating dosimetry values for a specific individual generally does not exceed ±15%. We believe, therefore, that our individualized approach, while still susceptible to uncertainty from the input values, will prove to be an improvement on existing methods. Ultimately, we expect head-to-head clinical trials to determine the extent to which these uncertainties influence our model's efficacy compared to existing dosing methods. We anticipate that such trials will demonstrate that our approach has great potential to enhance the radiation dose that can be safely delivered to many patients with neuroendocrine tumors. Figure 6 was generated using Adobe ® Illustrator ® , Adobe Systems Incorporated, version 12. 
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Appendix A
Analytic Proof
In this section, we provide an analytic proof of the claim that under the conditions [1], combined radiopharmaceutical therapy is superior to single agent therapy. As mentioned previously, we need only consider the values of the objective function at the two vertices which occur on the X-and Y-axes and the one created by the intersection of the constraint lines, which will be referred to as P int for the remainder of the discussion. The conditions [1] yield the region of feasibility shown ( Figure 6 ).
The vertices corresponding drug 1 and drug 2 single agent therapy are the points , respectively.
The third vertex of interest, P int , can easily be shown to be the point . The claim is that under such conditions, the optimal value of Z = t 1 X + t 2 Y is achieved at P int , rendering the optimal combination of drug dosages to be: Figure 6 : The inequality, , means that the line aX + bY = L 1 is steeper than the line cX + dY = L 2 . The shaded region is our region of feasibility.
We proceed by calculating the difference between the radiation dose to the tumor under combined agent therapy and the radiation dose to the tumor under each of the single agent therapies. Proving the claim is equivalent to showing that this difference is positive in both cases. The proof proceeds as follows:
Recall that the dose to the tumor, Z, is calculated by Z = t 1 X + t 2 Y so the dose to the tumor under combined agent therapy is . Likewise, the dose to the tumor under drug 1 single agent therapy is and the dose to the tumor under drug 2 single agent therapy is .
First, consider , the difference between the dose to the tumor under combined agent therapy and the dose to the tumor under drug 1 single agent therapy. A series of straight-forward algebraic manipulations shows that Note that and a > 0 imply a(adcb) > 0. In addition, implies at 2bt 1 > 0. Also, referring to Figure   3 it is clear to see that under our hypotheses, , implying that aL 2 -cL 1 > 0. Thus, . In other words, the dose to the tumor under combined agent therapy is greater than the dose to the tumor by drug 1 single agent therapy.
Next consider , the difference between the dose to the tumor under combined agent therapy and the dose to the tumor under drug 2 single agent therapy. Similar algebraic manipulation shows that Thus, the dose to the tumor under combined therapy is also greater than the dose to the tumor by drug 2 single agent therapy. Therefore, we may conclude that P int is the optimal solution and may state the common conclusion of the above proofs in the following theorem:
If organ 1 is the limiting critical organ for drug 1, organ 2 is the limiting critical organ for drug 2 and the patient specific parameters are such that , then the maximum value of Z = t 1 X+t 2 Y is attained at P int .
